Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.
Himawan FernandoThy DuongKevin HuynhJonathan NoonanJames A ShawStephen J DuffyZiad NehmeKaren SmithPaul Stewart MylesPeter J MeikleKarlheinz PeterDion StubPublished in: European heart journal (2021)
Unlike fentanyl, lignocaine does not impair the bioavailability or delay the antiplatelet effect of ticagrelor. Both drugs were well tolerated and effective with a high level of patient satisfaction for procedural analgesia. Routine procedural analgesia during percutaneous coronary intervention should be reconsidered and if performed, lignocaine is a beneficial alternative to fentanyl.
Keyphrases
- percutaneous coronary intervention
- patient satisfaction
- pain management
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- antiplatelet therapy
- acute myocardial infarction
- coronary artery disease
- coronary artery bypass grafting
- ultrasound guided
- postoperative pain
- chronic pain
- study protocol
- coronary artery bypass
- atrial fibrillation
- phase iii
- clinical trial
- clinical practice
- phase ii
- randomized controlled trial
- left ventricular